David Westenberg
Stock Analyst at Piper Sandler
(4.22)
# 273
Out of 5,182 analysts
186
Total ratings
50.49%
Success rate
15.96%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Initiates: Neutral | $21 | $20.40 | +2.94% | 1 | Apr 10, 2026 | |
| GRAL GRAIL | Initiates: Neutral | $54 | $49.47 | +9.16% | 1 | Apr 10, 2026 | |
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $65.42 | +98.72% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $85.70 | +51.69% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $8.14 | +59.71% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $266.36 | +12.63% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $569.95 | +31.59% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $132.72 | +28.09% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $23.13 | +29.70% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $119.04 | +13.41% | 16 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.5 → $10 | $9.24 | +8.23% | 14 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $78.82 | +90.31% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $25.24 | -24.72% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $54.42 | +47.00% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.63 | +22.70% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $196.11 | +17.28% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $16.13 | +85.99% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.61 | +62.69% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $191.46 | +4.46% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $14.08 | +42.05% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $12.69 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $27.75 | - | 1 | Nov 21, 2017 |
Caris Life Sciences
Apr 10, 2026
Initiates: Neutral
Price Target: $21
Current: $20.40
Upside: +2.94%
GRAIL
Apr 10, 2026
Initiates: Neutral
Price Target: $54
Current: $49.47
Upside: +9.16%
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $65.42
Upside: +98.72%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $85.70
Upside: +51.69%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $8.14
Upside: +59.71%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $266.36
Upside: +12.63%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $569.95
Upside: +31.59%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $132.72
Upside: +28.09%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $23.13
Upside: +29.70%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $119.04
Upside: +13.41%
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $9.24
Upside: +8.23%
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $78.82
Upside: +90.31%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $25.24
Upside: -24.72%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $54.42
Upside: +47.00%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.63
Upside: +22.70%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $196.11
Upside: +17.28%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $16.13
Upside: +85.99%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.61
Upside: +62.69%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $191.46
Upside: +4.46%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $14.08
Upside: +42.05%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $12.69
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $27.75
Upside: -